SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
- NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
- 07/07/2025
|
August 25, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SRPT
- NEW YORK , July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 07/07/2025
|
INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
- NEW YORK , July 7, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025 , inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm prior to the August 25, 2025 lead plaintiff motion deadline.
- 07/07/2025
|
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
- 07/06/2025
|
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- SAN DIEGO, July 05, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta's top executives with violations of the Securities Exchange Act of 1934.
- 07/05/2025
|
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.
- 07/04/2025
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
- NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025.
- 07/04/2025
|
Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit
- SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases.
- 07/03/2025
|
Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT
- NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
- 07/03/2025
|
SRPT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
- SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Sarepta business and prospects, resulting in its stock trading at inflated prices.
- 07/03/2025
|
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
- NEW YORK , July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 07/03/2025
|
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 07/03/2025
|
Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT
- NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
- 07/02/2025
|
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
- NEW YORK , July 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 07/02/2025
|
INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
- NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”).
- 07/02/2025
|
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
- 07/02/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/02/2025
|
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
- LOS ANGELES , July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
- 07/02/2025
|
SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- SAN DIEGO , July 1, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v.
- 07/01/2025
|
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , July 1, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sarepta securities between June 22, 2022 and June 24, 2025, both dates inclusive (the "Class Period").
- 07/01/2025
|
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
- NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025.
- 07/01/2025
|
SAREPTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sarepta securities between June 22,2023 and June 24, 2025, both dates inclusive (the “Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 06/30/2025
|
Shareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class Action
- SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases.
- 06/30/2025
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 53 individuals hired by Sarepta in the second quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule.
- 06/30/2025
|
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , June 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
- 06/30/2025
|
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
- SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP
- 06/30/2025
|
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
- SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta's top executives with violations of the Securities Exchange Act of 1934.
- 06/30/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/28/2025
|
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
- NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025.
- 06/28/2025
|
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
- NEW YORK , June 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 06/27/2025
|
Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). Sarepta is a commercial-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law F.
- 06/27/2025
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)
- NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”).
- 06/27/2025
|
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
- SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Sarepta business and prospects, resulting in its stock trading at inflated prices.
- 06/27/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/27/2025
|
2 Beaten-Down Stocks to Avoid
- Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period.
- 06/27/2025
|
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
- SAN DIEGO , June 26, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v.
- 06/26/2025
|
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
- 06/26/2025
|
Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 06/26/2025
|
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SRPT--SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 06/26/2025
|
Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Sarepta Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of August 25, 2025
- MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) securities between June 22, 2023, and June 24, 2025, inclusive. You are hereby notified that the class action lawsuit Dolgicer, Jr. v.
- 06/26/2025
|
SRPT SECURITIES: Lose Money on Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Contact BFA Law about the Pending Securities Fraud Investigation
- NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
- 06/26/2025
|
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
- The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.'s SRPT Elevidys treatment and evaluating the need for further regulatory action.
- 06/25/2025
|
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
- Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.
- 06/25/2025
|
FDA investigates patient deaths after treatment with Sarepta's gene therapy
- The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta Therapeutics' gene therapy, Elevidys.
- 06/24/2025
|
SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT)
- NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
- 06/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/23/2025
|
SRPT FRAUD ALERT: Sarepta Therapeutics, Inc. Investors are Reminded of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT)
- NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
- 06/22/2025
|
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
- Earlier this week, Sarepta Therapeutics, Inc SRPT provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-ambulatory patients.
- 06/20/2025
|
SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT)
- NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
- 06/20/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/18/2025
|
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
- In another tragic incident, Sarepta Therapeutics NASDAQ: SRPT saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute liver failure (ALF) after doctors treated them with ELEVIDYS.
- 06/18/2025
|
SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)
- NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
- 06/18/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/17/2025
|
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law
- NEW YORK--(BUSINESS WIRE)---- $SRPT #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Why is Sarepta being Investigated? Sarepta is a biopharmaceutical company focused on developing treatments.
- 06/17/2025
|
SRPT Stock: What's Happening With Sarepta Therapeutics?
- Sarepta Therapeutics (NASDAQ: SRPT) suffered a devastating blow on Monday, June 16 when its stock plummeted 42% following news of a second patient death linked to its Duchenne muscular dystrophy gene therapy, Elevidys. The biotechnology company and its global partner Roche immediately suspended commercial and clinical use of the treatment in non-ambulatory patients pending a comprehensive safety review.
- 06/17/2025
|
Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy
- Jared Holz, Mizuho, joins 'Fast Money' to talk the fallout for Sarepta after another death related to its muscular dystrophy gene therapy.
- 06/16/2025
|
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
- Sarepta Therapeutics, Inc. plunged over 47% after a second ELEVIDYS-related patient death, raising serious safety concerns and leading to trial suspensions. Despite the negative headlines and slashed FY25 guidance, I see the current valuation as deeply oversold and think long-term investors are best positioned to add at current levels. ELEVIDYS revenue dipped sequentially but remains up 180% year-over-year, and overall product revenue grew 70%, in my opinion, reflecting underlying business strength.
- 06/16/2025
|
Sarepta Therapeutics Stock Alert: Investors of Sarepta May Have Legal Claims and Are Encouraged to Contact Kehoe Law Firm, P.C. - SRPT
- PHILADELPHIA, PA / ACCESS Newswire / June 16, 2025 / Kehoe Law Firm, P.C. is investigating potential violations of federal securities laws and claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT).
- 06/16/2025
|
Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance
- CNBC's Angelica Peebles reports on the latest news regarding Sarepta.
- 06/16/2025
|
SRPT Down Near 9-Year Low, CSCO Upgrade, ROKU Using AMZN Ads
- Sarepta Therapeutics (SRPT) sold off more than 40% after suspending its Elevidys Duchenne muscular dystrophy drug, which was linked to two fatal liver failure cases. Diane King Hall break takes a closer look into the report.
- 06/16/2025
|
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
- Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
- 06/16/2025
|
Sarepta Therapeutics stock drops following second death linked to gene therapy Elevidys
- Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged almost 45% after the company disclosed the death of a second patient from acute liver failure linked with its experimental gene therapy Elevidys for Duchenne muscular dystrophy (DMD). In response, the company is convening an independent expert panel to evaluate and develop an enhanced immunosuppressive regimen, including sirolimus, to reduce the risk of acute liver failure in non-ambulatory DMD patients treated with Elevidys, with any new protocol subject to Food and Drug Administration (FDA) review and approval.
- 06/16/2025
|
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
- Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for ambulatory patients, and Sarepta is proactively addressing safety via enhanced immunosuppression and trial amendments. Valuation appears depressed, with the market pricing in a worst-case scenario, but historical precedent (ZOLGENSMA) suggests recovery is possible if risks are managed.
- 06/16/2025
|
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
- 06/16/2025
|
Sarepta Stock Crashes After Death of Second Patient Receiving Its Gene Therapy
- A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug's outlook.
- 06/16/2025
|
Sarepta shares tumble on second patient death after gene therapy treatment
- Shares of Sarepta Therapeutics plunged 34% in premarket trading on Monday, a day after the company disclosed a second case of patient death due to acute liver failure after receiving its gene therapy for a rare form of muscular dystrophy.
- 06/16/2025
|
Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
- Sarepta's stock collapsed due to ELEVIDYS safety concerns, regulatory setbacks, and reduced revenue guidance, but I see potential upside at current prices. ELEVIDYS's safety profile, especially in non-ambulatory patients, led to shipment suspension and a significant reduction in peak sales estimates. Despite setbacks, Sarepta's first-mover advantage, deep pipeline, and gene therapy leadership support a high-risk, high-reward investment thesis.
- 06/16/2025
|
Sarepta reports second case of liver failure death after its gene therapy treatment
- Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular dystrophy.
- 06/15/2025
|
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of.
- 06/15/2025
|
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 06/05/2025
|
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
- With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
- 06/05/2025
|
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration. “This is one of the first programs to receive platform technology designation.
- 06/04/2025
|
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. EN.
- 05/21/2025
|
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study of ELEVIDYS (delandistrogene moxeparvovec-rokl) for the treatment of Duchenne muscular dystrophy. Treatment with ELEVIDYS in the ENDEAVOR participants in cohort 6 who were 2 years old at the time of treatment (n=6), demonstrated mean expression of 93.
- 05/16/2025
|
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore
- Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound.
- 05/14/2025
|
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals ages 3- to less than 8-years-old, who do not have any deletions in exo.
- 05/13/2025
|
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
- Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even when trading near its 52-week low.
- 05/13/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/10/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 05/09/2025
|
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 05/09/2025
|
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities Health Care Conference at the Encore Hotel in Las Vegas, Nev. on Wednesday, May 14, 2025 at 8:40 a.m. P.T./11:40 a.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/eve.
- 05/08/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/08/2025
|
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
- Sarepta Therapeutics, Inc.'s gene therapy SRP-9003 for LGMD 2E/R4 subtype progresses, with potential BLA submission in H2 2025, possibly boosting shareholder value. SRPT rating changed from "Strong Buy" to "Hold" due to uncertainty around sales of DMD drug ELEVIDYS and patient death investigation still underway. Financial risks include potential need for additional funds, possibly diluting shareholders, despite Q1 2025 revenue increase of 70% YoY.
- 05/07/2025
|
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
- Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.
- 05/07/2025
|
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade
- Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show mixed SRPT performance: revenue beat expectations, but EPS missed, and cash reserves dropped significantly. ELEVIDYS uptake slowed by safety concerns and a temporary clinical trial hold, causing reduced revenue guidance and cautious market adoption.
- 05/07/2025
|
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
- SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
- 05/07/2025
|
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
- Sarepta Therapeutics, Inc. SRPT posted a loss for the first quarter on Tuesday.
- 05/07/2025
|
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
- 05/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/07/2025
|
Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, IR Doug Ingram - President and CEO Dallan Murray - EVP, CCO Louise Rodino-Klapac - EVP, Head of R&D, CSO Ian Estepan - EVP, CFO Conference Call Participants Tazeen Ahmad - Bank of America Securities Ritu Baral - TD Cowen Louise Chen - Scotiabank Andrew Tsai - Jefferies Eliana Merle - UBS Brian Abrahams - RBC Capital Markets Debjit - Guggenheim Securities Salveen Richter - Goldman Sachs Brian Skorney - Baird Michael Ulz - Morgan Stanley Gil Blum - Needham & Company Joe Schwartz - Leerink Partners Yanan Zhu - Wells Fargo Kostas Biliouris - BMO Capital Markets Anupam Rama - JPMorgan Biren Amin - Piper Sandler David Hoang - Deutsche Bank Rick Miller - Cantor Fitzgerald Andreas Argyrides - Oppenheimer & Co. Gena Wang - Barclays Operator Good afternoon, and welcome to the Sarepta Therapeutics First Quarter 2025 Financial Results Conference Call. As a reminder, today's program is being recorded.
- 05/06/2025
|
Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics
- The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 05/06/2025
|
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.73 per share a year ago.
- 05/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 05/05/2025
|
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES , May 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/05/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/03/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/02/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/01/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/30/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT
- NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 04/29/2025
|
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
- Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2025
|
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES , April 29, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/29/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/28/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 04/25/2025
|
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES , April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/23/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/22/2025
|
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarept.
- 04/22/2025
|
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
- 04/21/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 04/21/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/20/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/18/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/16/2025
|
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
- Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.
- 04/16/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/15/2025
|
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4. SRP-9005 for LGMD type 2C/R5: Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (OTP), Sarepta is cleared to proceed with dosing in Study SRP-9005-101 (COMPASS) in the U.S. COMPASS is.
- 04/15/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/14/2025
|
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
- RADNOR, Pa. , April 12, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ("Sarepta").
- 04/12/2025
|
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
- RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”). On March 18, 2025, Sarepta issued a press release revealing that a 16-year-old boy had passed away from acute liver failure following treatment with Sarepta's gene therapy, ELEVIDYS. On this news, Sarepta's stock price fell $27.81 per shar.
- 04/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , April 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/08/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 04/07/2025
|
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
- As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
- 04/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/04/2025
|
Sarepta halts three studies testing gene therapy for muscle disorder
- Sarepta Therapeutics said on Friday it would temporarily halt three trials testing its gene therapy Elevidys.
- 04/04/2025
|
Sarepta Therapeutics Provides Update on ELEVIDYS
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Following the safety update on acute liver failure that was issued on March 18, European Union (EU) reference member country authorities requested that the independent data monitoring committee (DMC).
- 04/04/2025
|
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
- Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The therapy has been developed in collaboration with pharma giant Roche RHHBY.
- 04/04/2025
|
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
- In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
- 04/03/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect
- NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 04/03/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 04/02/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/02/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/01/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 04/01/2025
|
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
- The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
- 04/01/2025
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 39 individuals hired by Sarepta in the first quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule.
- 03/31/2025
|
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
- Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
- 03/31/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/31/2025
|
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/31/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/30/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 03/30/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/28/2025
|
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/28/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/27/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/27/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 03/26/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/26/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK , March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/25/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/24/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/24/2025
|
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
- We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
- 03/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/23/2025
|
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/23/2025
|
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
- Things are going from bad to worse for Sarepta Therapeutics (SRPT 0.84%), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive.
- 03/23/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/21/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/21/2025
|
Sarepta: Should Investors Run For The Exit?
- Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolated incident, influenced by the patient's recent CMV infection, and not indicative of systemic issues. With over 800 patients treated and no similar cases, we expect the stock to recover, presenting a buying opportunity for risk-tolerant investors.
- 03/20/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/20/2025
|
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
- Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 03/20/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out
- NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
- 03/19/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/19/2025
|
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
- Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD).
- 03/19/2025
|
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 03/18/2025
|
3 Gene Therapy Stocks to Watch Amid Industry Turmoil
- Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.
- 03/18/2025
|
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
- U.S. stocks traded lower midway through trading, with the S&P 500 falling around 1% on Tuesday.
- 03/18/2025
|
Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death
- Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has died following treatment with its gene therapy ELEVIDYS. Although acute liver injury is a known potential side effect of ELEVIDYS and similar therapies, this level of severity had not been previously reported, the company said in a statement.
- 03/18/2025
|
Sarepta Therapeutics' stock falls after patient dies of liver failure
- The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
- 03/18/2025
|
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
- On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
- 03/18/2025
|
Sarepta says patient dies after treatment with gene therapy
- Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
- 03/18/2025
|
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
- Sarepta Therapeutics' stock is at 52-week lows despite strong Q4 earnings and promising clinical updates, reflecting broader biotech sector challenges and investor sentiment. Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD, and DM1, with significant market potential, though not as large as DMD.
- 03/04/2025
|
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne. “In the past decade, there have been significant advancements in the tr.
- 02/28/2025
|
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
- SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
- 02/27/2025
|
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Gena Wang - Barclays Andrew Tsai - Jefferies Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Joe Schwartz - Leerink Partners Gil Blum - Needham & Company Ritu Baral - TD Cowen Brian Skorney - Baird David Hoang - Deutsche Bank Ry Forseth - Guggenheim Securities Priyanka Grover - JPMorgan Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore Sami Corwin - William Blair Leo Watson - Mizuho Operator Good afternoon. And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
- 02/26/2025
|
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
- Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago.
- 02/26/2025
|
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2024. “2024 performance represented the fruition of our multi-year strategy to become a self-sustaining profitable biotech dedicated to improving the lives of patients with rare genetic disease. After obtaining a broad label for our gene therapy ELEVIDYS covering the vast majority of Duchenn.
- 02/26/2025
|
Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 02/26/2025
|
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 02/17/2025
|
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate. "Sarepta's financial strength and the positive outlook for our business provide us with the flexibility to use non-dilutive financing by establishing a revolving credit facility. It supplements our strong balance sheet and allows for contingent.
- 02/14/2025
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 26, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website a.
- 02/12/2025
|
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
- PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 milli.
- 02/10/2025
|
2 Growth Stocks to Buy Hand Over Fist in February
- Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring.
- 02/09/2025
|
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
- Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
- 02/03/2025
|
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Crossover-treated patients, those who received a placebo in Part 1 and.
- 01/27/2025
|
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
- Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns, but totality of evidence suggests it may be the best available treatment for DMD, with no immediate rivals.
- 01/16/2025
|
Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan
- Sarepta + Arrowhead +0.18 (+0.97%)
- 01/13/2025
|
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. Financial Update* (preliminary and unaudited): Total net product revenue of $638.2 million for the fourth quarter and $1.79 bi.
- 01/13/2025
|
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
- LUND, Sweden , Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference.
- 01/07/2025
|
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
- The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
- 01/06/2025
|
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. The presentation will be webcast live under the Events & Presen.
- 01/06/2025
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq List.
- 12/31/2024
|
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
- Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.
- 12/20/2024
|
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
- Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
- 12/19/2024
|
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
- The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
- 12/19/2024
|
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is t.
- 12/18/2024
|
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
- We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
- 12/17/2024
|
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
- New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need.
- 12/13/2024
|
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
- The consensus price target hints at a 48% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 12/13/2024
|
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 12/09/2024
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Lis.
- 11/29/2024
|
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
- The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
- 11/29/2024
|
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
- Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
- 11/27/2024
|
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
- The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 11/27/2024
|
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. The agreement will add meaningfully to S.
- 11/26/2024
|
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
- Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025 and a potential BLA filing by mid-2025. Despite strong revenues, Sarepta may need to raise additional funds within the next 12 months to support ongoing operations and development programs from its pipeline.
- 11/08/2024
|
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
- Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
- 11/07/2024
|
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Douglas Ingram - President and Chief Executive Officer Dallan Murray - Executive Vice President and Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Andrew Tsai - Jefferies Anupam Rama - JPMorgan Danielle Brill - Raymond James Eliana Merle - UBS Gil Blum - Needham & Company Ritu Baral - TD Cowen Joseph Schwartz - Leerink Partners Kostas Biliouris - BMO Capital Markets Brian Skorney - Baird Kristen Kluska - Cantor Fitzgerald Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore ISI Leo Watson - Mizuho Sami Corwin - William Blair Operator Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
- 11/07/2024
|
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 11/06/2024
|
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 6, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sar.
- 10/23/2024
|
2 High-Flying Growth Stocks With Massive Upside Potential
- These innovative drugmakers have potential catalysts ahead.
- 10/17/2024
|
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
- These two could become direct competitors relatively soon.
- 10/03/2024
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 28 individuals hired by Sarepta in September 2024. The equity awards were approved in accordance with Nasdaq L.
- 09/30/2024
|
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle Society 2024 Congress (WMS 2024), taking place Oct. 8-12, 2024, in Prague, Czechia. Among the data to be presented are new safety and efficacy results from several studies in the delandistrogene moxeparvovec clinical development program, including data from Studies 9001-101, 9001-103 (ENDEAVOR) and 9.
- 09/26/2024
|
Sarepta Therapeutics Muscles Up In DMD Race
- Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success on secondary measures like motor function improvement and time-to-rise. SRPT expects substantial revenue growth, projecting net product revenues of $2.9-3.1 billion by 2025.
- 09/18/2024
|
3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
- Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.
- 09/18/2024
|
These 2 Biotech Stocks Are Set to Soar
- Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.
- 09/13/2024
|
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 09/06/2024
|
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. on Friday, Sept. 6, 2024, at 9:15 a.m. E.T. The presentation will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarep.
- 08/30/2024
|
Bull Signal Flashing for Sarepta Therapeutics Stock
- After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.
- 08/19/2024
|
Biotech Stock Flashing Bull Signal
- Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level.
- 08/14/2024
|
2 Biotech Stocks to Buy Hand Over Fist in August
- Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.
- 08/12/2024
|
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
- Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 08/09/2024
|
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
- Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.
- 08/08/2024
|
7 Biotech Stocks to Buy for Their Game-Changing Potential
- With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
- 08/08/2024
|
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/07/2024
|
3 Genomics Stocks That May Transform Personalized Medicine
- When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the genetic drivers of disease than ever before.
- 08/06/2024
|
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
- Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/05/2024
|
5 Biotech Stocks to Bet On Bright Industry Prospects
- New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
- 07/29/2024
|
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
- Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue growth and earnings, with a $130 billion cumulative U.S. revenue opportunity. The recent pullback is an attractive investment opportunity for long-term investors.
- 07/24/2024
|
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/19/2024
|
3 Biotech Stocks You Should Know About
- In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
- 07/17/2024
|
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
- Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/16/2024
|
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
- Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
- 07/08/2024
|
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
- Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials.
- 07/06/2024
|
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
- Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be used to treat patients who are 4 and older.
- 07/04/2024
|
Best Momentum Stocks to Buy for July 3rd
- SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
- 07/03/2024
|
1 Soaring Growth Stock to Buy and Hold for 10 Years
- Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially.
- 07/03/2024
|
New Strong Buy Stocks for July 3rd
- MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.
- 07/03/2024
|
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
- Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
- 06/26/2024
|
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
- The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Friday, June 21. This move came after the company secured the U.S. FDA approval for its Duchenne muscular dystrophy gene therapy – Elevidys – for all patients aged four and older.
- 06/25/2024
|
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
- Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/24/2024
|
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
- Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary endpoint, ELEVIDYS hit key secondary endpoints, leading to FDA approval for all DMD patients ages 4 and older. Now with a label that covers roughly 80% of the DMD population, Sarepta is positioned for explosive growth in the DMD market.
- 06/22/2024
|
Sarepta CEO on what's next after expanded muscular dystrophy drug approval
- Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
- 06/21/2024
|
TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
- Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day in a year.
- 06/21/2024
|
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
- Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
- 06/21/2024
|
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
- SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) patients aged four and above. The call will be hosted by David Maris, a six-time #1 ranked pharma analyst and partner at Wall Street Beats. Maris stated, "Sarepta's expanded label approval for ELEVIDYS is a.
- 06/21/2024
|
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
- This biotech stock surged after one of its gene therapies was approved by the Food and Drug Administration.
- 06/21/2024
|
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
- Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
- 06/21/2024
|
Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment
- Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.
- 06/21/2024
|
Sarepta Therapeutics Stock Soars on FDA Approval
- Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.
- 06/21/2024
|
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
- Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 years old with Duchenne muscular dystrophy.
- 06/21/2024
|
Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use
- Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use of its gene therapy Elevidys for patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic condition which causes weakness and the wasting away of the body's muscles, with symptoms including trouble walking and running, falling frequently, fatigue and learning disabilities or difficulties.
- 06/21/2024
|
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
- Sarepta Therapeutics (NASDAQ: SRPT ) stock jumped about 30% overnight after the Food and Drug Administration (FDA) approved one of its gene therapies for children with Duchenne muscular dystrophy (DMD). Peter Marks, director of the Center for Biologics Evaluation and Research, overruled three research teams and his top lieutenants in making the decision.
- 06/21/2024
|
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
- Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in children, which especially affects boys.
- 06/21/2024
|
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
- Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.
- 06/21/2024
|
Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.
- The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
- 06/21/2024
|
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
- Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.
- 06/21/2024
|
Sarepta surges as investors cheer expanded use of gene therapy
- Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular dystrophy (DMD).
- 06/21/2024
|
Why has the Sarepta stock price (SRPT) gone up more than 35%?
- Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hours trading last night. But why? Ground-breaking medical breakthrough Toward the end of the trading day yesterday, Sarepta announced that it had obtained approval from the U.S.
- 06/21/2024
|
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
- Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
- 06/20/2024
|
Sarepta Therapeutics receives expanded approval for Elevidys
- Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the company's treatment for Duchenne muscular dystrophy.
- 06/20/2024
|
US FDA approves expanded use of Sarepta's Duchenne gene therapy
- The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday.
- 06/20/2024
|
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the expanded U.S. FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above.
- 06/20/2024
|
Sarepta Therapeutics: Navigating Elevidys Upside Potential
- Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. If successful, Elevidys label and geographic expansion is likely to unlock Sarepta's capacity to maintain a strong revenue growth pattern. Thus, supporting a “buy” rating for SRPT.
- 06/17/2024
|
Pfizer's gene-therapy trial failure boosts Sarepta's stock
- Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
- 06/13/2024
|
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
- If a portfolio is passively managed, investors tend to buy and forget. This however holds true for high-quality blue-chip and growth stocks.
- 06/06/2024
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 9 individuals hired by Sarepta in May 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5.
- 05/31/2024
|
Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?
- Sarepta Therapeutics (NASDAQ:SRPT) is set to make a significant move by entering the S&P MidCap 400 index, replacing Shockwave Medical. This change, effective before trading begins on June 3, 2024, follows Johnson & Johnson's acquisition of Shockwave Medical.
- 05/30/2024
|
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
- Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.
- 05/04/2024
|
Gene Therapy Pioneer Jerry R. Mendell, M.D.
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propell.
- 05/03/2024
|
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
- Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
- 05/02/2024
|
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/01/2024
|
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
- Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.97 per share a year ago.
- 05/01/2024
|
Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Douglas Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
- 05/01/2024
|
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024. “We are pleased to announce another strong quarter of growth from our four approved therapies, posting net product revenue of $359.5 million, a 55% increase over the same quarter of the prior year, and achieving profitability on a GAAP and non-GAAP basis,” said Doug Ingram, president and chief execut.
- 05/01/2024
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The.
- 04/30/2024
|
Why Sarepta (SRPT) Might Surprise This Earnings Season
- Sarepta (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/30/2024
|
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sare.
- 04/24/2024
|
GSK Gears Up for Q1 Earnings: Here's What to Expect
- We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
- 04/23/2024
|
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
- Sarepta Therapeutics reported strong Q4/2023 performance, with $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial, showed significant improvements in motor function and secondary endpoints, keeping the potential for label expansion alive. SRPT's growth prospects, including potential label expansion for ELEVIDYS, have led to an updated strategy and bullish outlook for the company.
- 04/11/2024
|
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
- Sarepta Therapeutics will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has already taken a beating.
- 04/08/2024
|
2 Biotech Stocks to Buy Hand Over Fist in April
- Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.
- 04/06/2024
|
Outperforming ETF manager names a potential ‘50-bagger' in the stock market
- The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-market index, but Michael Taylor, the fund's lead manager, has done that so far.
- 04/06/2024
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The.
- 03/29/2024
|
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 03/29/2024
|
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
- Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.
- 03/13/2024
|
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
- Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid demand for residential solar solutions.
- 03/08/2024
|
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
- Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.
- 03/04/2024
|
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
- Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
- 02/29/2024
|
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
- 02/28/2024
|
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/28/2024
|
Is It Too Late to Buy Sarepta Therapeutics Stock?
- Sarepta Therapeutics faced some issues last year, but it earned approval for an important medicine. The biotech is on the verge of another key regulatory nod that should help improve its financial results.
- 02/28/2024
|
Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)
- Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/27/2024
|
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
- Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
- 02/21/2024
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update. The event will be webcast live under the investor relati.
- 02/21/2024
|
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/20/2024
|
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
- Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
- 02/19/2024
|
Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?
- Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/19/2024
|
Why Sarepta Therapeutics Stock Is Soaring Today
- The U.S. FDA accepted Sarepta's efficacy supplement filing for DMD gene therapy Elevidys. This filing could lead to the removal of age and ambulation restrictions for Elevidys.
- 02/16/2024
|
U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy
- Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wasting disorder.
- 02/16/2024
|
Gene therapy: Why does it cost millions for a single treatment?
- Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
- 02/15/2024
|
5 Biotech Stocks to Consider for Your Portfolio in 2024
- New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
- 02/13/2024
|
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
- PTC Therapeutics could soon lose one of its major products in the E.U. Sarepta Therapeutics competes in the same disease market as PTC.
- 02/11/2024
|
PepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 data
- PepGen Inc. NASDAQ: PEPG is a clinical-stage biotech focused on developing therapies for rare neuromuscular and neurological genetic diseases like Duchenne muscular dystrophy (DMD). PepGen utilizes its proprietary enhanced delivery oligonucleotide (EDO) platform to create a pipeline of disease-modifying gene therapies.
- 02/06/2024
|
Sarepta says its experimental Duchenne drug more effective than older medicine
- Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51.
- 01/29/2024
|
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
- Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.
- 01/25/2024
|
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
- Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystrophy. The company's FDA-approved products, including Elevidys and three RNA-targeted injections, have shown strong financial results in Q3 2023. The possible expansion label for Elevidys granted by the FDA could extend the target age group, increasing its growth potential.
- 01/24/2024
|
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
- Sarepta Therapeutics Inc. NASDAQ: SRPT is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. This medical sector company specializes in the treatment of Duchenne muscular dystrophy (DMD), a congenital myopathy that occurs in one in 3,600 male live-born infants in the United States.
- 01/23/2024
|
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
- An analyst made a major change to his take on the biotech. He raised his price target considerably.
- 01/22/2024
|
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet
- The consensus price target hints at a 29.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 01/22/2024
|
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
- For many biotech stocks, price and performance hinges on the success of a drug in testing. This means most biotech companies rely on one market opportunity to succeed financially.
- 01/16/2024
|
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
- Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
- 01/10/2024
|
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
- The future of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy looked grim two months ago. There's been a 180 since.
- 01/10/2024
|
5 Mid-Cap Stocks to Buy in a Volatile January
- We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.
- 01/10/2024
|
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
- Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 01/10/2024
|
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
- Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.
- 01/09/2024
|
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
- Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Tuesday after positive comments were made by its CEO at the JPMorgan Healthcare Conference. Sarepta Therapeutics CEO Douglas Ingram said that the company could see expanded use cases for Elevidys.
- 01/09/2024
|
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
- Sarepta Therapeutics boasts excellent innovative abilities and a deep pipeline. DexCom still has a huge growth runway left in the continuous glucose monitoring market.
- 01/09/2024
|
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
- REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
- 01/05/2024
|
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
- Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental treatment DYNE-101 showed early dose-dependent results in patients with myotonic dystrophy type 1, Dyne said in a release.
- 01/03/2024
|
New Strong Buy Stocks for January 3rd
- GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
- 01/03/2024
|
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 8, 2024 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. The presentation will be webcast live under the Events & Present.
- 01/02/2024
|
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
- Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 12/29/2023
|
3 Things About Sarepta Therapeutics Every Smart Investor Knows
- Sarepta Therapeutics recently launched a new medicine. It already has several on the market, but the company isn't yet profitable.
- 12/28/2023
|
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
- Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
- 12/26/2023
|
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
- Sarepta Therapeutics and Vertex Pharmaceuticals already have a lot in common. Sarepta's focus market has a few peculiarities that could pose a problem.
- 12/22/2023
|
5 Biotech Acquisition Targets To Accumulate In 2024
- Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.
- 12/21/2023
|
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
- Sarepta has encountered several issues related to its gene therapy for Duchenne muscular dystrophy. The small biotech is still generating solid financial results and has an extensive pipeline of programs.
- 12/17/2023
|
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
- Sarepta Therapeutics has multiple treatments for Duchenne muscular dystrophy, a rare genetic disorder. Its gene therapy Elevidys obtained accelerated approval this year, but recent data from a clinical trial fell short of expectations.
- 12/09/2023
|
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 12/01/2023
|
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
- We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
- 11/20/2023
|
3 Monster Stocks in the Making
- Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare genetic diseases.
- 11/18/2023
|
3 Stocks You'll Regret Not Buying Soon: November 2023
- The recent surge in official interest rates, the most substantial in 40 years, is anticipated to impact aggregate demand significantly. This could potentially result in a GDP reduction of approximately 4 percent for the current year, followed by an additional 1% decrease in 2024.
- 11/16/2023
|
Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock Now
- Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 11/13/2023
|
Insider Buys: Lumen, Air Products, Inari, Remitly and Sarepta
- Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
- 11/10/2023
|
Is Sarepta Therapeutics Stock a Bad-News Buy?
- Sarepta released results of its phase 3 trials last week for Elevidys, which fell short of expectations. The company, however, remains optimistic that a label expansion for its gene therapy remains possible.
- 11/09/2023
|
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
- Not all technology companies are the same. In fact, not all chipmakers are the same.
- 11/08/2023
|
Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test
- Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.
- 10/31/2023
|
Why Sarepta Therapeutics Stock Is Crashing Today
- Sarepta's DMD drug Elevidys failed to meet the primary endpoint in a phase 3 study. However, the company plans to pursue an expanded label for the drug anyway.
- 10/31/2023
|
Why Are Stocks Down Today?
- Stocks are down today and investors wondering why have come to the right place as we have an answer to that question! Several factors are weighing on the stock market and keeping shares down today.
- 10/31/2023
|
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?
- Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Tuesday after the biopharmaceutical company announced results from a Phase 3 clinical trial. That clinical trial covers the use of ELEVIDYS as a treatment for patients ages four to seven suffering from Duchenne muscular dystrophy.
- 10/31/2023
|
Sarepta shares slump as muscle disorder therapy fails to meet key trial goal
- Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the treatment securing full U.S. approval.
- 10/31/2023
|
Sarepta Stock Sinks on Mixed Gene Therapy Results
- In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.
- 10/31/2023
|
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy
- Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.
- 10/30/2023
|
Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial
- Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.
- 10/30/2023
|
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2023 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sar.
- 10/25/2023
|
Are Gene Therapy Stocks The Market's Next Big Winners?
- It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘
- 09/25/2023
|
2 Top Growth Stocks to Buy With $500
- Sarepta Therapeutics is successfully developing treatments for a rare and devastating disease. Shopify's recent moves should make it even stronger in the fast-growing e-commerce industry.
- 09/14/2023
|
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T. The fireside chat will be held at the Sheraton New York in New York, NY. The presentation will be webcast live under the Events & Presentations section of the investor relation.
- 09/05/2023
|
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
- Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some important challenges that could stunt its growth.
- 08/23/2023
|
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
- CRISPR Therapeutics is using a novel technique to develop innovative therapies. Sarepta Therapeutics is developing medicines targeting a difficult-to-treat disease.
- 08/22/2023
|
Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head of Research & Development Dallan Murray - EVP & Chief Customer Officer Ian Estepan - EVP & CFO Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capital Markets Tazeen Ahmad - Bank of America Gena Wang - Barclays Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Uy Ear - Mizuho Securities Michael Ulz - Morgan Stanley Danielle Bongero - Raymond James Ritu Baral - TD Cowen Anupam Rama - JPMorgan Kristen Kluska - Cantor Fitzgerald John Boyle - William Blair Debjit Chattopadhyay - Guggenheim Securities Operator Good afternoon and welcome to the Sarepta Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode.
- 08/02/2023
|
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates
- Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to loss of $2.65 per share a year ago.
- 08/02/2023
|
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2023
|
Sarepta Therapeutics: 'Hold' Amid Market Myopia
- Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impacted the stock but could expand with a successful confirmatory trial. Despite challenges, SRPT continues to progress, suggesting a viable long-term investment with a 'Hold' recommendation.
- 07/13/2023
|
3 Biotech Stocks to Sell Before They Damage Your Portfolio
- There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.
- 07/12/2023
|
Sarepta (SRPT) Sells Priority Review Voucher for $102M
- Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.
- 07/06/2023
|
Sarepta Therapeutics completes sale of priority review voucher for $102 million
- Sarepta Therapeutics Inc. SRPT, -0.90% said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million and will use the proceeds for R&D. Sarepta was awarded the voucher by the Food and Drug Administration after the agency granted accelerated approval of Elevidys for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
- 07/05/2023
|
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T. The fireside chat will be held virtually. The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta's website at https://invest.
- 07/03/2023
|
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
- Sarepta recently secured conditional approval for its gene-editing therapy. But the therapy's high price tag might slow down its uptake among patients.
- 06/30/2023
|
Sarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goals
- Doug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get revoked, and more.
- 06/29/2023
|
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
- On May 15, Sarepta Therapeutics Inc. NASDAQ: SRPT learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA) advisors. Naturally, the stock jumped more than 30% to a two-year high.
- 06/27/2023
|
Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy
- Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.
- 06/23/2023
|
Sarepta slumps as concerns emerge around upcoming gene therapy data
- Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use.
- 06/23/2023
|
Sarepta's Gene Therapy Approval Lands With a Thud
- The $3.2 million one-time treatment is the first gene therapy approved to treat DMD, a progressive and fatal condition that manifests in early childhood.
- 06/23/2023
|
Sarepta Therapeutics downgraded at Evercore ISI after FDA approval of gene therapy
- Sarepta Therapeutics Inc. SRPT, -2.33%, which yesterday scored a win with U.S. Food and Drug Administration approval of the first gene therapy for children with Duchenne muscular dystrophy, was downgraded Friday by analysts who are skeptical that Sarepta can expand the treatment's narrow label. The treatment, Elevidys, was approved under the FDA's accelerated approval pathway, which gives patients access to promising new treatments while the company conducts trials to confirm the expected clinical benefit.
- 06/23/2023
|
Sarepta Therapeutics announces FDA approval of first gene therapy to treat Duchenne muscular dystrophy
- Sarepta Therapeutics Inc (NASDAQ:SRPT) said the US Food and Drug Administration (FDA) has accelerated approval for ELEVIDYS, its first-of-a-kind gene therapy for Duchenne muscular dystrophy (DMD). DMD is an inherited progressive muscle-wasting disorder that generally affects young boys.
- 06/23/2023
|
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids
- WASHINGTON — The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's ability to help boys with the inherited disease.
- 06/22/2023
|
FDA Approves Sarepta's Gene Therapy for Duchenne Muscular Dystrophy
- The decision marks the first approval of a gene therapy to treat DMD, a fatal and progressive disease that manifests in young children.
- 06/22/2023
|
Sarepta Stock Yo-Yoes After Winning Highly Anticipated Gene Therapy Nod
- Sarepta won approval Thursday for its highly anticipated Duchenne muscular dystrophy gene therapy. SRPT stock yo-yoed in response.
- 06/22/2023
|
Sarepta gets FDA approval for rare genetic disorder treatment
- Sarepta Therapeutics Inc. SRPT, +0.60% said Thursday that the Food and Drug Administration approved its Elevidys gene therapy to treat the rare genetic disorder Duchenne muscular dystrophy, or DMD. Sarepta shares rose 2% in recent activity, following a brief halt, while the S&P 500 index SPX, +0.17% was up 0.2%.
- 06/22/2023
|
US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids
- The U.S. drug regulator on Thursday granted accelerated approval to Sarepta Therapeutics' first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD), an inherited progressive muscle wasting disorder that almost always affects young boys.
- 06/22/2023
|
Sarepta Therapeutics: Value Proposition Ahead Of DMD Gene Therapy Decision
- Sarepta Therapeutics should earn ~$1bn from its Duchenne Muscular Dystrophy franchise in 2023 - although the company has made eye-watering losses in recent years. Sarepta ought to hear any day whether the FDA has granted accelerated approval for its gene therapy DMD candidate SRP-9001. This catalyst will likely significantly move the share price needle. SRP-9001 could become a new standard of care in DMD. Mgmt. has suggested the peak revenue opportunity could exceed $4bn.
- 06/22/2023
|
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
- Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements.
- 06/12/2023
|
Frank Sands' Top 1st-Quarter Buys
- Sands Capital Management recently disclosed its 13F portfolio updates for the first quarter of 2023, which ended on March 31.
- 06/06/2023
|
Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 06/01/2023
|
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
- The FDA has delayed its decision on Sarepta's gene therapy, SRP-9001, and investors are concerned. An approval could still be coming, but it may be narrower in scope.
- 06/01/2023
|
Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
- The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
- 05/25/2023
|
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
- Sarepta focuses on gene therapies to treat rare diseases. SRP-9001 is designed to correct the genetic mutation that can cause Duchenne muscular dystrophy.
- 05/24/2023
|
Sarepta Therapeutics shares fall as FDA delays decision on gene therapy
- Sarepta Therapeutics shares fell by more than 12% on the news the US Food and Drug Administration (FDA) requires more time for its review of the company's Biologics License Application (BLA) of its investigational gene therapy SRP-9001 for Duchenne muscular dystrophy. The company said the FDA requires additional time to complete the review, including final label negotiations and postmarketing commitment discussions, and it expects to complete the review by June 22, 2023, almost a month later than its previous regulatory action date of May 29.
- 05/24/2023
|
Biotech Stock Drops on FDA Update
- Sarepta Therapeutics Inc (NASDAQ:SRPT) is gaining some attention in the biotech realm today.
- 05/24/2023
|
2 Under-the-Radar Biotech Stocks to Buy in 2023
- Exelixis and Sarepta are relatively small players in the highly competitive biotech industry. Both drugmakers have found success by focusing most of their efforts on niche areas.
- 05/24/2023
|
Sarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy.
- Investors on Wednesday seemed to take the delay as a sign that opponents of approval within the agency were winning out.
- 05/24/2023
|
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
- The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble. The post Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy appeared first on Investor's Business Daily.
- 05/24/2023
|
FDA defers decision for Sarepta's gene therapy to June 22
- The U.S. Food and Drug Administration has deferred its decision on an accelerated approval for Sarepta Therapeutics Inc's gene therapy for a muscle wasting disorder called Duchenne muscular dystrophy from May 29 to June 22, the company said on Wednesday.
- 05/24/2023
|
Sarepta says FDA is working toward accelerated approval of its latest treatment for Duchenne muscular dystrophy
- Sarepta Therapeutics Inc. SRPT, -1.45% said Wednesday that the U.S. Food and Drug Administration has indicated after talks with the company that it's working toward granting accelerated approval of SRP-9001, its latest treatment for Duchenne muscular dystrophy, or DMD. The agency said that's subject to the completion of its Biologics License Application (BLA) review and that it would initially be for use in patients aged 4 to 5 years old.
- 05/24/2023
|
Why These 3 Nasdaq Stocks Buckled Today
- The Federal Trade Commission is suing to block the proposed merger between Amgen and Horizon Therapeutics. This adverse regulatory action rippled out across the small- and mid-cap biotech landscape today.
- 05/16/2023
|
Sarepta Therapeutics: A Virtual Monopoly In Duchenne Muscular Dystrophy
- Last week, an FDA advisory committee voted in favor of approving Sarepta Therapeutics, Inc.'s SRP-9001 for treating DMD. Sarepta Therapeutics stock has good near-term momentum as the BLA is scheduled for May 29.
- 05/16/2023
|
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
- Sarepta Therapeutics Inc. NASDAQ: SRPT jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company's experimental gene therapy to treat Duchenne muscular dystrophy.
- 05/16/2023
|
FDA board votes to approve gene therapy for Duchenne muscular dystrophy
- David Nierengarten, Wedbush Securities managing director, joins 'Closing Bell Overtime' to discuss Sarepta shares after the FDA panel votes to approve gene therapy for Duchenne muscular dystrophy.
- 05/15/2023
|
Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
- The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.
- 05/15/2023
|
Why Is Sarepta (SRPT) Stock Up 29% Today?
- Sarepta (NASDAQ: SRPT ) stock is on the move Monday as investors react to news of FDA advisors voting on its gene therapy for Duchenne muscular dystrophy. The big news here is the FDA advisors voting in favor of the agency supporting the gene therapy treatment.
- 05/15/2023
|
Sarepta Therapeutics shares soar on FDA panel's support for muscular dystrophy therapeutic
- Sarepta Therapeutics shares added almost 25% on Monday morning after the US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee voted eight to six in favor of the accelerated approval of the company's therapeutic SRP-9001 for Duchenne muscular dystrophy (DMD). The company said the vote, while not binding, would be considered by the FDA when considering the potential accelerated approval of SRP-9001.
- 05/15/2023
|
Why Sarepta Therapeutics Stock Is Skyrocketing Today
- An FDA advisory committee voted 8-6 in favor of accelerated approval for SRP-9001. The FDA doesn't have to go along with the advisory committee's recommendation, but usually does.
- 05/15/2023
|
2 Supercharged Growth Stocks to Buy Right Now
- Growth stocks have been top-performers during the first five months of 2023. This broad-based rally is in danger of stalling because of numerous storm clouds on the horizon.
- 05/14/2023
|
FDA advisers narrowly back accelerated approval of Sarepta gene therapy
- U.S. Food and Drug Administration advisers voted 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.'s gene therapy for Duchenne muscular dystrophy despite questions about its clinical benefit and safety.
- 05/12/2023
|
Sarepta Therapeutics stock halted premarket ahead of FDA panel meeting on new Duchenne muscular dystrophy treatment
- Sarepta Therapeutics Inc. stock SRPT, -0.88% was halted premarket Friday, ahead of a meeting of a Food and Drug Administration advisory panel to discuss the company's SRP-9001 gene therapy for the rare genetic disorder Duchenne muscular dystrophy, or DMD. DMD typically affects boys.
- 05/12/2023
|
Why Sarepta Therapeutics Stock Faded This Week
- Sarepta Therapeutics is heading into an important expert panel review this Friday for its Duchenne muscular dystrophy gene therapy candidate. The FDA's briefing documents ahead of this meeting raised concerns about the therapy's efficacy and safety.
- 05/11/2023
|
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
- Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
- 05/03/2023
|
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Mary Jenkins – Associate Director-Investor Relations Doug Ingram – President and Chief Executive Officer Louise Rodino-Klapac – Executive Vice President, Head-R&D and Chief Scientific Officer Dallan Murray – Executive Vice President and Chief Customer Officer Ian Estepan – Executive Vice President and Chief Financial Officer Conference Call Participants Colin Bristow – UBS Gena Wang – Barclays Brian Abrahams – RBC Capital Markets Judah Frommer – Credit Suisse Salveen Richter – Goldman Sachs Gil Blum – Needham and Company Tazeen Ahmad – Bank of America Danielle Brill – Raymond James Mike Ulz – Morgan Stanley Neena Bitritto-Garg – Citi Tim Lugo – William Blair Kristen Kluska – Cantor Fitzgerald Hartaj Singh – Oppenheimer and Company Debjit Chattopadhyay – Guggenheim Joseph Schwartz – SVB Securities Zhiqiang Shu – Berenberg Gavin Clark-Gartner – Evercore ISI Brian Skorney – Baird Anupam Rama – JPMorgan Operator Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2023 Earnings Call. At this time all participants are in a listen-only mode.
- 05/02/2023
|
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago.
- 05/02/2023
|
These Are the Top 10 Holdings of Avoro Capital Advisors
- Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
- 04/17/2023
|
Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy
- Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.
- 04/14/2023
|
Sarepta shares tumble as concerns mount over FDA approval on gene therapy
- CNBC's Meg Tirrell joins 'Power Lunch' to discuss the Sarepta's gene therapy for muscular dystrophy, and why the stock is taking a tumble over doubts around Sarepta receiving FDA approval.
- 04/13/2023
|
Sarepta Therapeutics Tumbles on Gene Therapy Drama
- A report raised questions about the chances for approval of the company's gene therapy to treat Duchenne muscular dystrophy.
- 04/13/2023
|
Sarepta Therapeutics shares fall as report says FDA almost rejected its gene therapy
- Sarepta Therapeutics Inc (NASDAQ:SRPT) shares took a beating Thursday as Stat News reported that reviewers at the US Food and Drug Administration (FDA) were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by the company. The “non-binding conclusion" prompted FDA official Peter Marks to intervene earlier this year and schedule an advisory meeting on May 12, Stat said citing three people with direct knowledge of the agency deliberations.
- 04/13/2023
|
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
- Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday that sent SRPT stock into a dive. The post Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy appeared first on Investor's Business Daily.
- 04/13/2023
|
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
- Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. According to these reports, regulators at the FDA were originally planning to reject the company's request for approval of SRP-9001.
- 04/13/2023
|
2 Top Growth Stocks That Could Soar This Spring
- An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could extend patent-protected exclusivity for Regeneron's biggest revenue stream.
- 04/06/2023
|
Sarepta Stock Has $30 to $40 Upside if Panel on Gene Therapy Drug Positive, Says Analyst
- Citi analyst Neena Bitritto-Garg initiates coverage on shares of Sarepta with a Buy rating.
- 04/04/2023
|
3 Up-and-Coming Growth Stocks to Buy Right Now
- Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.
- 03/25/2023
|
Why did Sarepta Therapeutics Stock Plummet?
- The middle of March may be when many people celebrate St. Patrick's Day, but it was an unlucky time for Sarepta Therapeutics (NASDAQ: SRPT). Unfortunately, the United States Food and Drug Administration recently announced they need time to investigate data on the company's new Duchenne Muscular Dystrophy (DMD) treatment.
- 03/21/2023
|
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?
- Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 03/21/2023
|
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001
- Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.
- 03/17/2023
|
Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?
- Sarepta Therapeutics (NASDAQ: SRPT ) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA. According to a press release, the company will meet with the FDA prior to May 29, 2023, to discuss the development of SRP-9001.
- 03/17/2023
|
Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy
- In a surprise decision, the FDA will hold an advisory committee to discuss Sarepta's gene therapy, and SRPT stock tanked Friday. The post Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy appeared first on Investor's Business Daily.
- 03/17/2023
|
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meeting
- Sarepta Therapeutics Inc. SRPT shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said it required an advisory committee meeting for its experimental Duchenne muscular dystrophy drug. Shares of Sarepta dropped as much as 20% after hours, following a 2.9% gain in the regular session to close at $149.67.
- 03/16/2023
|
2 Biotech Stocks To Watch In March 2022
- Check out these 2 biotech stocks in the stock market today.
- 03/16/2023
|
Sarepta Therapeutics: Time To Change My Game Plan After Q4 Earnings
- Sarepta Therapeutics recently reported their Q4 and full-year 2022 earnings with a minor miss on EPS and a solid beat on revenue. The market reacted positively moving SRPT up. The company continues to report solid growth trends for EXONDYS, VYONDYS, and AMONDYS. Notably, this growth is not coming from increases in prices.
- 03/04/2023
|
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
- The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.
- 03/02/2023
|
Sarepta's stock still up after Tuesday's announcement that its Duchenne drug candidate won't require a FDA AdCom meeting
- Shares of Sarepta Therapeutics Inc. SRPT were up 18.7% in trading on Wednesday afternoon, a day after the company told investors that the Food and Drug Administration does not plan to schedule an advisory committee meeting for its experimental Duchenne muscular dystrophy drug. Sarepta made the announcement as part of its fourth-quarter earnings.
- 03/01/2023
|
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
- Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
- 03/01/2023
|
Sarepta Therapeutics pops as results top estimates and Morgan Stanley raises share price to $187
- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock rocketed after the drug company posted fourth quarter financial results that topped Wall Street estimates and Morgan Stanley (NYSE:MS) said the stock could rally nearly 50%. For the period ended December 31, 2022, the Massachusetts-based company reported an adjusted earnings per share loss of $0.53, which beat analyst estimates for a loss of $0.83 per share.
- 03/01/2023
|
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy
- Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed. The post Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy appeared first on Investor's Business Daily.
- 03/01/2023
|
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
- Sarepta Therapeutics (NASDAQ: SRPT ) stock is heading higher on Wednesday following the release of its latest earnings report. For the fourth quarter of 2022, Sarepta Therapeutics reported adjusted earnings per share of -53 cents.
- 03/01/2023
|
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
- Markets are trying to rise, and these companies are helping out.
- 03/01/2023
|
Sarepta Therapeutics, Inc. (SRPT) Q4 2022 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Louise Rodino-Klapac - Executive Vice President, Head of R&D and Chief Scientific Officer Dallan Murray - Senior Vice President & Chief Customer Officer Ian Estepan - Executive Vice President & Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Brian Abrahams - RBC Colin Bristow - UBS Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Robert Fink - Guggenheim Gena Wang - Barclays Ritu Baral - Cowen Judah Frommer - Credit Suisse Gil Blum - Needham Danielle Brill - Raymond James Hartaj Singh - Oppenheimer Yun Zhong - BTIG Richard Miller - Cantor Gavin Clark-Gartner - Evercore Operator Good afternoon and welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, today's conference call is being recorded.
- 02/28/2023
|
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2023
|
Sarepta stock surges more than 10% as results top expectations, drug given priority review
- Sarepta Therapeutics Inc. SRPT shares rallied in the extended session Tuesday after the biotech drug maker topped Wall Street expectations, and said U.S. regulators granted a priority review status for its muscular dystrophy drug candidate SRP-9001. Sarepta shares rallied as much as 14% after hours, following a 3.3% rise in the regular session to close at $122.13.
- 02/28/2023
|
7 Biotech Stocks That Will Make You Rich in 10 Years
- If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.
- 01/18/2023
|
Sarepta: Raised Financial Guidance, Looming Catalyst Makes This Worth A Look
- Sarepta Therapeutics, Inc. net product revenues for Q4 2022 are expected to come in about 32% higher at $235.5 million; Financial results for Q4 2022 are expected late February 2023. BLA of SRP-9001 for the treatment of patients with Duchenne Muscular Dystrophy was accepted November 2022, Priority Review date established for May 29, 2023.
- 01/17/2023
|
2 Under-the-Radar Biotech Stocks to Buy in 2023
- These biotechnology stocks are pushing ahead with promising innovations.
- 01/06/2023
|
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T. / 10:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T. / 10:50 a.m. P.T.
- 01/03/2023
|
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 12/02/2022
|
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
- The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
- 11/29/2022
|
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
- The FDA said Monday it will perform a speedy review of Sarepta Therapeutics' muscular dystrophy gene therapy, and SRPT stock jumped. The post Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy appeared first on Investor's Business Daily.
- 11/28/2022
|
Sarepa expected to get FDA decision on Duchenne treatment by May 29
- Shares of Sarepta Therapeutics Inc. SRPT, -0.15% were up 4.6% in premarket trading on Monday after the company said U.S. regulators accepted its application for accelerated approval of SRP-9001, its experimental treatment for Duchenne muscular dystrophy. The Food and Drug Administration is expected to make a decision whether to approve SRP-9001 by May 29.
- 11/28/2022
|
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
- CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T. The fireside chat will be held virtually.
- 11/23/2022
|
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
- Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
- 11/03/2022
|
Sarepta Therapeutics, Inc. (SRPT) Q3 2022 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager, IR Doug Ingram - President and CEO Ian Estepan - EVP and CFO Dallan Murray - SVP and Chief Customer Officer Dr. Louise Rodino-Klapac - EVP, Head of R&D and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Tazeen Ahmad - BofA Gil Blum - Needham & Company Colin Bristow - UBS Matthew Harrison - Morgan Stanley Brian Abrahams - RBC Brian Skorney - Baird Tim Lugo - William Blair Anupam Rama - JP Morgan Hartaj Singh - Oppenheimer Anvita Gupta - Cowen Yun Zhong - BTIG Zhiqiang Shu - Berenberg Gavin Clark-Gartner - Evercore ISI Operator Good afternoon, and welcome to the Sarepta Therapeutics Third Quarter 2022 Earnings Call. As a reminder, today's program is being recorded.
- 11/02/2022
|
3 Unstoppable Stocks That Could Double in 5 Years
- The opportunities for these innovators are tremendous.
- 10/29/2022
|
2 Under-the-Radar Biotech Stocks to Buy in 2022
- These two drugmakers are growing in prominence.
- 10/19/2022
|
Stock Market Rallies Powerfully Off Lows; Lamb Weston, Sarepta, AMN In Focus | Stock Market Today
- But it's too early to declare a market bottom. Stock Market Today: October 5, 2022 Hosts: Ali Coram & Ken Shreve Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: https://www.investors.com Like us on Facebook: https://www.facebook.com/investorsbusinessdaily Follow us on Twitter: https://twitter.com/IBDinvestors Follow us on Instagram: https://www.instagram.com/investorsbusinessdaily/ Follow us on StockTwits: https://stocktwits.com/InvestorsBusinessdaily Follow us on LinkedIn: https://www.linkedin.com/company/investors-business-daily Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 10/05/2022
|
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
- If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
- 09/30/2022
|
Sarepta prices almost $1 billion convertible bond offering
- Sarepta Therapeutics Inc. SRPT, -9.77% said Wednesday it has priced $980 million of convertible senior unsecured notes that mature in September of 2027. The company will reduce the potential dilution of issuing new shares by entering capped call transactions with one or more dealers.
- 09/14/2022
|
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
- Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
- 09/12/2022
|
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
- CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. E.T. The fireside chat will be held at the Sheraton New York.
- 09/06/2022
|
Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 09/01/2022
|
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
- In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.
- 08/30/2022
|
Sarepta: Advancement In DMD Space With SRP-9001 And Licensed MyoAAV
- BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. The global market opportunity for Duchenne Muscular Dystrophy is expected to reach $4.11 billion by 2023.
- 08/10/2022
|
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
- Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
- 08/03/2022
|
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/02/2022
|
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?
- Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 08/01/2022
|
Why Sarepta Therapeutics Stock Is Perking Up Today
- The biotech's gene therapy for Duchenne's muscular dystrophy could hit the market sooner than expected.
- 07/29/2022
|
Sarepta (SRPT) Stock Gains on FDA News
- Source: Panuwach/Shutterstock Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment. According to the company, it plans to seek a Biologics License Application (BLA) for accelerated approval of SRP-9001 from the U.S. Food and Drug Administration (FDA).
- 07/29/2022
|
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
- Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche.
- 07/06/2022
|
Sarepta Has New Gene Therapy Data Coming. What It Could Mean for the Stock.
- Sarepta will update investors Thursday on the data it hopes will persuade U.S. regulators to accelerate approval of its gene therapy treatment for muscular dystrophy.
- 07/06/2022
|
Sarepta stock plunges after FDA puts study on hold
- Sarepta Therapeutics Inc. SRPT, +5.14% shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration. Sarepta disclosed that a patient in a study of a proposed drug for Duchenne muscular dystrophy suffered a "serious adverse event of hypomagnesemia," or seriously low levels of magnesium in blood.
- 06/23/2022
|
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 06/03/2022
|
Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
- CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday June 14, 2022 at 10:00 a.m. P.T./ 1:00 p.m. E.T. The fireside chat will be held at the Terranea Resort, Rancho Palos Verdes, CA.
- 06/02/2022
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q1 2022 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Dallan Murray - Senior Vice President & Chief Customer Officer Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of R&D Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capital Markets Judah Frommer - Credit Suisse Brian Skorney - Baird Gil Blum - Needham & Company Hartaj Singh - Oppenheimer & Company Joseph Schwartz - SVB Securities Timothy Lugo - William Blair Kristen Kluska - Cantor Fitzgerald Yun Zhong - BTIG Operator Good afternoon, ladies and gentlemen. Welcome to the Sarepta Therapeutics First Quarter 2022 Earnings Call.
- 05/05/2022
|
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2022
|
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/27/2022
|
Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
- CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, May 4, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2022 financial results and to provide a corporate update.
- 04/27/2022
|
Sarepta: The DMD Leader
- Sarepta is the unrivalled leader in the DMD (or Duchenne Muscular Dystrophy) space. Their revenue stream is growing tremendously over the years.
- 04/26/2022
|
7 Potential Biotech Stocks Buyout Targets in 2022
- Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products. The post 7 Potential Biotech Stocks Buyout Targets in 2022 appeared first on InvestorPlace.
- 04/21/2022
|
Why Is Sarepta Therapeutics (SRPT) Down 1.2% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 03/31/2022
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences:
- 03/02/2022
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2021 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2022
|
Steven Cohen's Interest in IDEAYA Increases
- Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.
- 02/25/2022
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
- CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2021 financial results and to provide a corporate update.
- 02/22/2022
|
Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
- Increase in revenue of $166.9 million observed with FDA approved DMD drugs in Q3 of 2021; year over year increase of 37%. Next-generation PPMO drugs are being advanced in order to improve upon the first generation types; in addition, other mutations observed in DMD are being targeted as well.
- 02/08/2022
|
Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate
- Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on its own as it prepares for a pivotal readout in mid-year. According to Lysogene, Sarepta returned the global commercial rights for LYS-SAF302 after “unsuccessful discussions for transferring back to Lysogene the responsibility for the global commercial supply of LYS-SAF302.
- 01/13/2022
|
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 10:30 a.m. E.T. / 7:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:50 a.m. E.T. / 7:50 a.m. P.T.
- 01/06/2022
|
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
- Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
- 12/27/2021
|
These 5 Loser Stocks of 2021 Could be Big Winners in 2022
- The momentum in the equity markets is expected to stay on firm-footing in 2022. DQ, PINS, SRPT, YY and CD have a chance to outperform next year.
- 12/21/2021
|
Why Is Sarepta Therapeutics (SRPT) Down 4.4% Since Last Earnings Report?
- Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
- 12/03/2021
|
4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
- Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.
- 11/26/2021
|
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
- The biotech stock fell a little more than $72 since its close last Friday.
- 11/04/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2021 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 67.74% and 11.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2021
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences:
- 11/02/2021
|
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
- CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2021 financial results and to provide a corporate update.
- 10/27/2021
|
Is This Beaten Down Biotech a Bad News Buy?
- It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
- 10/20/2021
|
What's Next For Sarepta Stock After A 12% Fall?
- The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterday, while it is down 14% in the last five trading days. In comparison, the broader S&P500 index.
- 10/18/2021
|
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
- Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
- 10/14/2021
|
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
- CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of 6,172,840 shares of its common stock at a price to the public of $81.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 925,926 shares of its common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $500.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about October 18, 2021, subject to customary closing conditions.
- 10/13/2021
|
Why Sarepta Therapeutics Tumbled Today
- Investors weren't wowed by a company update, or by news of a fresh stock issue.
- 10/13/2021
|
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
- CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021.
- 10/12/2021
|
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
- CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 in shares of its common stock.
- 10/12/2021
|
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
- Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for Duchenne muscular dystrophy. SRP-9001, being developed in partnership with Roche Holdings AG (OTC: RHHBY), is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue.
- 10/11/2021
|
Sarepta Therapeutics' SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
- CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data from its SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) development program and details of Study SRP-9001-301, known as EMBARK, its global pivotal Phase 3 trial of SRP-9001 for the treatment of Duchenne muscular dystrophy. SRP-9001, being developed in partnership with Roche, is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
- 10/11/2021
|
Sarepta, Codiak Nix Exosome Therapy Development Pact
- Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option agreement early. The termination will be effective as of December 3, 2021.
- 10/08/2021
|
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
- CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today celebrated the grand opening of the Genetic Therapies Center of Excellence (GTCOE), its new research facility in Columbus, Ohio.
- 10/04/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 43 individuals hired by Sarepta in September 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 09/30/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Cantor Fitzgerald 2021 Virtual Global Healthcare Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Cantor Fitzgerald 2021 Virtual Global Healthcare Conference (Transcript)
- 09/27/2021
|
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
- - Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful - Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will Be Eligible to Enroll in Part B of MOMENTUM
- 09/27/2021
|
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
- CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, 2021. This year's presentations at WMS 2021 highlight scientific leadership and innovation from across Sarepta's deep, multi-platform portfolio and reflect the Company's continued commitment advancing life-changing therapies to those with rare genetic diseases.
- 09/14/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
- 09/13/2021
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:
- 09/07/2021
|
How Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008?
- We believe that Sarepta Therapeutics stock, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying opportunity at the present time. SRPT stock trades under $80 levels currently and it is.
- 09/07/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in August 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/31/2021
|
4 Underpriced Healthcare Stocks That Wall Street Adores
- A drug maker, two insurers, and a medical-device company pass our screen of healthcare concerns with high analysts ratings and upside potential.
- 08/19/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q2 2021 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children's Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
- – Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses
- 08/04/2021
|
Sarepta Therapeutics's Earnings: A Preview
- Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its next round of earnings this Wednesday, August 04. For all of the relevant information, here is your guide for Wednesday's Q2 earnings announcement.
- 08/03/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in July 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/30/2021
|
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
- CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2021 financial results and to provide a corporate update.
- 07/28/2021
|
Sarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks
- Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years.
- 07/01/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/30/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Bank of America Securities 2021 Napa BioPharma Virtual Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Bank of America Securities 2021 Napa BioPharma Virtual Conference (Transcript)
- 06/16/2021
|
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
- Tuesday's futures were fairly positive after a somewhat mixed start to the week.
- 06/15/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
- 06/10/2021
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:
- 06/03/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 28, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 6 individuals hired by Sarepta in May 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/28/2021
|
3 Popular Stocks Money Managers Couldn't Stop Selling in Q1
- Institutional investors and hedge funds wanted nothing to do with these widely owned stocks in the first quarter.
- 05/28/2021
|
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
- Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
- 05/19/2021
|
Sarepta Therapeutics (SRPT) Moves 8.4% Higher: Will This Strength Last?
- Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 05/19/2021
|
Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday
- Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.
- 05/18/2021
|
Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)
- 05/18/2021
|
Sarepta's stock is up 11% on positive data from clinical trial for Duchenne treatment
- Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the company shared positive data from a mid-stage, open-label clinical trial for its experimental Duchenne muscular dystrophy treatment. The data comes from the first 11 enrolled participants in a study of 20 participants who are between the ages of 4 and 7 years old.
- 05/18/2021
|
Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material
- CAMBRIDGE, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, an open-label study known as ENDEAVOR being conducted in partnership with Roche. In results from the first clinical study using commercially representative material, SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) demonstrated robust expression of micro-dystrophin and no new safety signals from prior studies, supporting its potentially differentiated profile for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
- 05/18/2021
|
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 12-week expression and safety results from Study SRP-9001-103 (Study 103), also known as ENDEAVOR. Study 103 is the first clinical trial using Sarepta's commercially representative material for SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
- 05/17/2021
|
5 Growth Stocks Down 50% (or More) With Upside of 62% to 133%, According to Wall Street
- Analysts believe these fast-growing, innovative businesses are excellent bounce-back candidates over the next 12 months.
- 05/11/2021
|
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
- Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline.
- 05/06/2021
|
Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech
- The company's revenue soared in Q1, but its bottom line still looked ugly.
- 05/06/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -4.48% and 4.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
- CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter of 2021.
- 05/05/2021
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:
- 05/04/2021
|
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
- CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051, its next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
- 05/03/2021
|
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
- CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, May 3, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present results from the 30 mg/kg arm of the MOMENTUM study, a multiple-ascending dose clinical trial of SRP-5051 for the treatment of Duchenne muscular dystrophy. SRP-5051 is the first investigational treatment using Sarepta's next-generation PPMO platform, which is designed around a proprietary cell-penetrating peptide conjugated to Sarepta's phosphorodiamidate morpholino oligomer (PMO) backbone with the goal of increasing drug concentration in muscle tissue.
- 04/30/2021
|
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
- CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Sarepta) (Nasdaq:SRPT) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC Capital) to purchase up to 2,000,000 shares of Sarepta common stock at a price of $68.50 per share in cash. TRC Capital's offer price is approximately 4.6% lower than the closing share price of Sarepta's common stock on April 16, 2021, the last business day prior to the commencement of the offer. The offer is for approximately 2.52% of the shares of Sarepta common stock outstanding.
- 04/26/2021
|
Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas
- Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.
- 04/20/2021
|
Is Sarepta Therapeutics Worthy of Redemption?
- A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.
- 04/01/2021
|
Edgewise Therapeutics Proposes Terms For $150 Million IPO
- Edgewise Therapeutics has filed to raise $150 million in an IPO.
- 03/23/2021
|
Can Sarepta's 'Remarkable' Gene Therapy Pull Shares Out Of The Dumps?
- An experimental gene therapy from Sarepta Therapeutics showed "remarkable" stability at two years in muscular dystrophy patients, an analyst said Friday as SRPT stock edged higher. The post Can Sarepta's 'Remarkable' Gene Therapy Pull Shares Out Of The Dumps?
- 03/19/2021
|
Sarepta Stock Has Been Battered. Positive Gene Therapy Data Sends Shares 5% Higher.
- The gene therapy, known as SRP-9003, treats a disorder called limb-girdle muscular dystrophy type 2E.
- 03/19/2021
|
Sarepta Therapeutics' Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
- -- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measured by western blot -- -- Mean NSAD score improvement of 5.7 points from baseline was sustained through 24 months in low-dose cohort, and mean NSAD score improvement of 4.0 points from baseline at one year in high-dose cohort -- -- Results in both cohorts continue to reinforce the safety and tolerability profile of SRP-9003 -- CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new results from the ongoing study of SRP-9003 (rAAVrh74.MHCK7.hSGCB), the Company's investigational gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E). In the first look at expression data from biopsies taken two years after a single administration of SRP-9003, results found sustained protein expression in muscle tissue. In functional outcomes assessments taken two years following treatment in Cohort 1 (low-dose cohort) and one year after treatment in Cohort 2 (high-dose cohort), patients continued to demonstrate stability in their NSAD (North Star Assessment for Dysferlinopathies) total score and improvements on timed function tests. Results are being presented today at the 2021 Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference.
- 03/18/2021
|
Exon-Skipping Franchise Buys Sarepta A Second Chance
- SRPT's lucrative Exon-Skipping franchise allows the company to buy a second chance, even if its SRP 9001 project fails.
- 03/17/2021
|
Rocket Pharmaceuticals Primed for Takeoff
- With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
- 03/15/2021
|
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
- -- Ten abstracts, including four podium presentations, reflect Sarepta's ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions -- CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, which will take place virtually March 15-18, 2021. Among the research that will be presented:
- 03/15/2021
|
Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels
- Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a good buying opportunity, given a large sell-off, and now there have been some positive developments for the.
- 03/02/2021
|
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
- Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
- 03/02/2021
|
Sarepta Therapeutics Drops on Earnings. Why Analysts Remain Hopeful.
- Sarepta Therapeutics stock fell as markets digested its bigger-than-expected quarterly loss. But analysts say the setup for the stock remains positive.
- 03/02/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript
- 03/02/2021
|
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
- Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -20.00% and 1.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Recap: Sarepta Therapeutics Q4 Earnings
- Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.20% over the past year to ($1.84), which missed the estimate of ($1.77).
- 03/01/2021
|
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
- – Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference –
- 03/01/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in February 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/26/2021
|
Earnings Preview: Sarepta Therapeutics
- Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.
- 02/26/2021
|
Sarepta stock rises after FDA approves biotech's Duchenne MD treatment
- Shares of Sarepta Therapeutics Inc. rose nearly 1% in late trading Thursday after the biotech company said the U.S. Food and Drug Administration has approved one of its treatments for Duchenne muscular dystrophy in patients with certain mutations. The continued approval of the injection, called amondys 45, could be contingent on confirmation of a clinical benefit in further trials, Sarepta said.
- 02/25/2021
|
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
- -- AMONDYS 45 is Sarepta's third RNA exon-skipping treatment for DMD approved in the U.S. ---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for patients and clinicians is available at www.SareptAssist.com -- CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AMONDYS 45 (casimersen). AMONDYS 45 is an antisense oligonucleotide from Sarepta's phosphorodiamidate morpholino oligomer (PMO) platform, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 45 skipping. This indication is based on a statistically significant increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45, which is reasonably likely to predict clinical benefit for those patients who are exon 45 amenable. Consistent with the accelerated approval pathway, the continued approval of AMONDYS 45 may be contingent on confirmation of a clinical benefit in confirmatory trials.
- 02/25/2021
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:
- 02/24/2021
|
Sarepta, Vertex & Neurocrine: Out Of Favor Healthcare Stocks To Watch
- Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines.
- 02/24/2021
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
- CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full year 2020 financial results and to provide a corporate update.
- 02/22/2021
|
What's in the Cards for Sarepta (SRPT) This Earnings Season?
- Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.
- 02/16/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 02/15/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 02/11/2021
|
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - February 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sarepta announced that its one-time gene therapy for Duchenne muscular dystrophy...
- 02/08/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- New York, New York--(Newsfile Corp. - February 6, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 02/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
- 02/04/2021
|
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
- CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the four winners of the Rare Lessons lesson planning competition. Sarepta has granted the winning authors $2,500 each and $2,500 to the educational institution with which each is affiliated. The winning submissions are now available on sharemylesson.com, and more information about the authors can be found at Sarepta.com/rarelessons.
- 02/04/2021
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws....
- 02/01/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in January 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 01/29/2021
|
After A 50% Fall Sarepta Therapeutics Stock Now Looks Attractive
- Sarepta Therapeutics stock, is a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases. SRPT stock is now at the same level it was on Mar 23, 2020, when broader markets made a bottom due to the spread of Covid-19.
- 01/22/2021
|
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
- Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
- 01/21/2021
|
Sarepta (SRPT) Inks New Gene Editing Research Collaboration
- Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.
- 01/14/2021
|
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
- -- Alliance will assess the use of Sarepta's proprietary gene editing technology and Genevant's proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for an exclusive license to Genevant's LNP technology for four neuromuscular indications --
- 01/13/2021
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.
- 01/12/2021
|
Sarepta Therapeutics: Bombs Away
- The biotech space remains one of my favorite sectors for outsized gains. With the potential for large gains needs to be balanced with far more volatility than seen in other sectors.
- 01/12/2021
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
- 01/11/2021
|
Here's Why Sarepta Therapeutics Lost Support on Wall Street
- Disappointing trial results caused a flock of analysts to drop their ratings on this biotech stock.
- 01/10/2021
|
SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT
- NEW YORK, Jan. 9, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially...
- 01/09/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.
- 01/08/2021
|
SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. – SRPT
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. On January 7, 2021, after market hours, Sarepta announced its gene therapy as a one-time treatment for the rare disorder Duchenne muscular dystrophy failed to show bene
- 01/08/2021
|
Why Tenet, CVS, Thermo Fisher And Sarepta Are Moving Today
- Tenet Healthcare (NYSE: THC) shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60. Tenet is a Dallas-based healthcare provider organization operating a collection of hospitals (65) and many outpatient facilities, including ambulatory surgery centers, urgent care centers, freestanding imaging centers, freestanding emergency rooms/micro-hospitals, and physician practices across the United States.
- 01/08/2021
|
SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging Today
- Shares of SRPT stock are getting hammered on Friday after Sarepta Therapeutics reported negative results from a treatment trial. The post SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging Today appeared first on InvestorPlace.
- 01/08/2021
|
Serepta Stock Nearly Halves After Failed Gene Therapy Study
- The shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have nearly halved this morning, down 49.8% at $84.90 at last check, after the company's experimental gene therapy to treat Duchene muscular dystrophy (DMD) did not meet the main goal of its study.
- 01/08/2021
|
Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate
- Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.
- 01/08/2021
|
Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
- Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge, Massachusetts-based Sarepta announced topline results from Part 1 of the Phase 2/3 study of SRP-9001, its investigational gene therapy to treat DMD, showing the study didn't achieve statistical significance on the primary functional endpoint of improvement in North Star Ambulatory Assessment, or NSAA, total score compared to placebo at 48 weeks after the treatment.
- 01/08/2021
|
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021 at 10:00 a.m. E.T. /7:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:20 a.m. E.T. /7:20 a.m. P.T.
- 01/08/2021
|
Sarepta stock plunges more than 50% after mixed results from drug study
- Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.
- 01/07/2021
|
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- -- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9001-treated participants showed an increase in NSAA total score compared to placebo at 48 weeks; however, the study did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to placebo at 48 weeks post-treatment --
- 01/07/2021
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in December 2020. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 12/31/2020
|
Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst
- Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: SRPT) render their stocks as top picks for the first half of 2021, according to an analyst at BofA Securities.
- 12/18/2020
|
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
- MENLO PARK, Calif.--(BUSINESS WIRE)---- $SRPT #PrecisionOncology--Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
- 12/17/2020
|
Sarepta Therapeutics Announces Executive Management Changes
- -- Ian Estepan named chief financial officer -- Dallan Murray named chief commercial officer -- Louise Rodino-Klapac, Ph.D., named chief scientific officer -- Ty Howton, general counsel, to retire from Sarepta -- Ryan Brown named interim general counsel
- 12/14/2020
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)
- 12/07/2020
|
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
- -- Results from the multiple - ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than eteplirsen, SRP-5051 at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping, and greater dystrophin production with no negative renal or other laboratory findings --
- 12/07/2020
|
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
- CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present interim data from the MOMENTUM study, a multiple-ascending dose clinical trial of SRP-5051 for the treatment of Duchenne muscular dystrophy. SRP-5051 is the first investigational treatment using Sarepta's next-generation PPMO platform, which is designed around a proprietary cell-penetrating peptide conjugated to Sarepta's phosphorodiamidate morpholino oligomer (PMO) backbone with the goal of increasing drug concentration in muscle tissue.
- 12/04/2020
|
Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)
- 12/02/2020
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 28 individuals hired by Sarepta in November 2020. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/30/2020
|
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
- CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, Dec. 2, 2020 at 3:30 p.m. E.T.
- 11/25/2020
|
Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020
- -- Sarepta is h onored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information submitted by employees to independent research company --
- 11/20/2020
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)
- 11/10/2020
|
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2020 Results - Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Sarepta Therapeutics Posts Mixed Third Quarter As Sales Miss
- Sarepta Therapeutics reported third-quarter losses of $1.42 per share on $121.4 million in sales late Thursday. But SRPT stock was flat in extended trades.
- 11/05/2020
|
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
- -- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical d osing is expected to begin b efore the end of 2020 --
- 11/05/2020
|
Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
- CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020 at 3:30 p.m. E.T.
- 11/02/2020
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2020. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 10/30/2020
|
Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
- A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. The post Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.
- 10/29/2020
|
Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
- CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2020 financial results after the Nasdaq Global Market closes on Thursday, November 5, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2020 financial results and to provide a corporate update.
- 10/29/2020
|
